Imatinib and dasatinib as salvage therapy for sclerotic chronic graft-vs-host disease

AIM: To assess the toxicity, tolerance, steroid-sparing capacity, effectiveness, and response rate to imatinib and dasatinib for the treatment of severe sclerotic chronic graft-vs-host disease (scGVHD). METHODS: This retrospective study analyzed 8 consecutive patients with severe refractory scGVHD w...

Descripción completa

Detalles Bibliográficos
Autores principales: Sánchez-Ortega, Isabel, Parody, Rocío, Servitje, Octavio, Muniesa, Cristina, Arnan, Montserrat, Patińo, Beatriz, Sureda, Anna, Duarte, Rafael F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Croatian Medical Schools 2016
Materias:
Graft-VS-Host Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937227/
https://www.ncbi.nlm.nih.gov/pubmed/27374826
http://dx.doi.org/10.3325/cmj.2016.57.247

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937227/
https://www.ncbi.nlm.nih.gov/pubmed/27374826
http://dx.doi.org/10.3325/cmj.2016.57.247

Ejemplares similares